WHO Grants Emergency Use Listing for Cepheid's Xpert® Hemorrhagic Fever Panel Test to Support Ebola Outbreak Response in the DRC
Extensive GeneXpert® Dx system footprint across Africa enables rapid deployment of decentralized molecular testing where it is needed most SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- Cepheid, a Danaher company and a leader in molecular diagnostics, today announced that it has...
Covered in this story
What has happened since
- Danaher Corporation is up 6.3% since this was published, 47 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Danaher Corporation
- UBS: $205 → $250 by Sep 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $DHR yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Danaher Corporation →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.